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both of which were signiﬁcantly faster than in previously published
studies. After T cell recovery, peripheral blood T cells moved from
the naive to the central memory fraction immediately, and then
moved to the effector memory fraction. A naive subset of CD4 T
cells remained (median: 38 cells/L on day 90, n  12) during the
ﬁrst 3 months, which was signiﬁcantly higher than in the BMT
control (median: 9 cells/L on day 90, n  5, p  0.015). To
investigate whether these T cells with memory phenotype are
functional, we analyzed antigen-speciﬁc T-cell recovery using cy-
tomegalovirus (CMV) as a speciﬁc antigen. CMV-responsive
CD4 T cells were detected within the ﬁrst 4 months in all
recipients with positive CMV antigenemia (n  13), but CD8 T
cells were detected only in 5 out of 13 cases. To conclude, naive
cord blood T cells rapidly increased in number and adopted a
memory phenotype showing cytokine-production and antigen-rec-
ognition capacity in the early phase after CBT. These data suggest
that mature T lymphocytes in cord blood have unique properties
and contribute to the favorable clinical outcome of CBT.
4
UMBILICAL CORD BLOOD TRANSPLANTATION AFTER A NON-MYELOA-
BLATIVE THERAPY IN HIGH RISK ADULTS AND ADOLESCENTS
Wagner, J.E., Brunstein, C., Barker, J. Blood and Marrow Transplant
Program, University of Minnesota, Minneapolis, MN
Bone marrow transplantation (BMT) in adults is associated with
a high risk of graft-versus-host disease (GVHD), opportunistic
infection and regimen related toxicity. For these reason, umbilical
cord blood (UCB) after a non myeloablative preparative regimen
has been explored. The underlying hypothesis is that umbilical
cord blood T cells will be sufﬁciently alloreactive to effect engraft-
ment in the non myeloablative setting. Fifty-one adults with ad-
vanced hematologic malignancies [median age 49 years (range
19-60)], ineligible for myeloablative conditioning by virtue of ad-
vanced age (73%), extensive prior therapy (42%) or serious co-
morbidities/poor ﬁtness (31%) received UCB transplantation
(UCBT) after cyclophosphamide 50 mg/kg, ﬂudarabine 200 mg/
m2, and 200 cGy TBI. Immunosuppression was with cyclospo-
rine-A to at least day 100 and mycophenolate mofetil to day 30.
Patients with no combination chemotherapy in the 6 months prior
to transplant also received ATG during conditioning. Approxi-
mately 1/4 received single and 3/4 received double UCB grafts.
Units were predominantly 1-2 antigen HLA mismatched with the
recipient. The incidence of sustained neutrophil engraftment of
donor origin was 89% (95% CI, 81-97) at a median of 8 days
(range 5-32). Stratiﬁed into those with and without chemotherapy
in the prior 4 months, the cumulative incidence of sustained donor
engraftment was 98% (95% CI: 94-100) and 64% (95% CI, 39-89)
(p  0.03). The incidence of platelet recovery (50,000/L) was
68% (95% CI, 53-83). The incidences of grade II-IV and grade
III-IV acute GVHD were 63% (95% CI: 49-73) and 25% (95%
CI: 14-36) at day 100, and chronic GVHD was 28% (95% CI:
16-40) at 1 year. TRM was 19% (95% CI: 9-29) at day 180.
Regression of relapsed or persistent disease has been seen in pa-
tients with myelodysplasia and intermediate and low grade lym-
phoid malignancies. The probability of overall survival at 1 year is
44% (95% CI: 30-58). Notably, only ﬁtness and not age was
associated with poor outcome. These data suggest that the regimen
is well tolerated and sufﬁcient for engraftment particularly in
patients with chemotherapy in the preceding 4 months. This ap-
proach extends access to transplant to many adults who would
otherwise be ineligible based on lack of donor and/or inability to
tolerate high-dose conditioning.
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COMPARISON OF ADULT ALLOGENEIC UMBILICAL CORD BLOOD
TRANSPLANTATION BETWEEN MYELOABLATIVE AND NON-MYELOAB-
LATIVE CONDITIONING REGIMENS
Tashiro, H.1, Kozai, Y.2, Goto, M.1, Noguchi, M.1, Shirasaki, R.1,
Kawasugi, K.1, Kodo, H.2, Shirafuji, N.2 1. Department of Hematology/
Oncology, Teikyo University School of Medicine, Tokyo, Japan; 2. Di-
vision of Transfusion Medicine, Fuchu Metropolitan Hospital
Aim: To make clear the feasibility of non-myeloablative condi-
tioning on adult allogeneic umbilical cord blood transplantation,
we compared the result between patients receiving the myeloabla-
tive transplantation and the non-myeloablative transplantation
(NST) in point of the engraftment, and the incidence of acute
GVHD.
Patients and Methods: Patients who were underwent umbilical
cord blood transplantation during May 1999 to Mar 2005 were
analyzed retrospectively. The myeloablative group: 30 patients
(median age, 33) with AML (n 10), ALL (n 10), NHL (n 6),
MDS (n  3), and CML (n  1). Conditioning consisted of total
body irradiation (TBI)-based regimens or busulfan-based ones.
GVHD prophylaxis was with cyclosporine (CyA) alone, CyA with
short-term Methotrexate (s-MTX), or Tacrolimus with s-MTX.
NST group: 22 patients (median age, 55) with AML (n  6), ALL
(n  1), MDS (n  3), CMMoL (n  1), NHL (n  7), HD (n 
3), and CLL (n  1). Conditioning regimen consisted mostly of
TBI combined with Fludarabine. GVHD prophylaxis was with
CyA, CyA with MMF, or Tacrolimus. The median transplanted
cell number, and HLA disparity were similar between two groups.
Results: The rate of engraftment failure including conditioning
failure, and autologous recovery was 27% in the myeloablative
group and 32% in NST group, respectively. Neutrophils were
engrafted at day 23 (median) and at day 21 in the myeloablative and
NST group, respectively. The cumulative incidence of grade
III-IV acute GVHD was 26% in the myeloablative group and 40%
in NST group, respectively.
Conclusion: There were no signiﬁcant differences in the prob-
ability of engraftment and in the duration to the engraftment of
neutrophils between two groups. The incidence of grade III-IV
GVHD in NST group was higher than that in the myeloablative
group. Further observations are needed to ascertain the feasibility
of NST using allogeneic umbilical cord blood.
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UMBILICAL CORD BLOOD (UCB) TRANSPLANTATION FOR INDOLENT
LYMPHOID MALIGNANCIES
Barker, J.N.1, Wagner, J.E.2 1. Memorial Sloan-Kettering Cancer
Center, New York, NY; 2. University of Minnesota, MN
Multiple studies have suggested patients with refractory or re-
current Non-Hodgkin’s lymphoma (NHL) can beneﬁt from allo-
geneic transplantation with reduced risk of post-transplant relapse
as compared to that seen after autologous transplantation due to a
graft-versus-lymphoma (GVL) effect. However, widespread appli-
cation of allografting has been limited by lack of suitable donors
and high transplant-related mortality (TRM) early post transplant
when conventional myeloablative conditioning is used. Non-my-
eloablative (NMA) conditioning is associated with reduced TRM
and has been successful in patients transplanted with matched
sibling donors for follicular NHL, chronic lymphocytic leukemia
(CLL), and mantle cell lymphoma (MCL). The University of
Minnesota has investigated NMA UCB transplantation (UCBT) in
patients without matched sibling donors using conditioning with
50 mg/kg Cyclophosphamide, 200 mg/m2 Fludarabine and 200
cGy TBI with cyclosporine and mycophenolate mofetil immuno-
suppression. This approach in patients with advanced hematologic
malignancies has been associated with a high incidence of sustained
donor engraftment and a low incidence of TRM despite older age
and/or extensive prior therapy provided the recipient has good
performance status. Sixteen patients aged 37-67 years with ad-
vanced or refractory follicular NHL (n 7), CLL (n 6) or MCL
(n  3) were transplanted using this approach. Thirteen had
sustained donor engraftment. Grade II–IV acute and extensive
chronic graft-versus-host disease (GVHD) was seen in 12 and 6
patients, respectively. Four patients (3 follicular NHL and 1 CLL)
have died with progressive disease and 12 are alive in complete
remission between 180 and 1214 days after transplant. Two of the
3 patients with failure of donor engraftment were salvaged with a
single cycle of CVP. This lack of intensive combination chemo-
therapy immediately prior to transplant may have contributed to
their risk for graft rejection. Two patients with follicular NHL
required the addition of Rituximab post-transplant to achieve re-
mission. Interestingly, 2 of 3 patients (both with CLL) who had
transient donor engraftment and subsequent graft rejection are in
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remission up to one year after transplant. In conclusion, the pre-
liminary results in indolent Non-Hodgkin’s lymphoma including
CLL and MCL are encouraging with 12 of 16 patients in sustained
complete remission. Prior therapy is likely an important factor in
donor engraftment and the incidence of severe GVHD has been
low. A GVL effect is suggested but the relationship with GVHD is
uncertain. The efﬁcacy of Rituximab in the post-transplant setting
is intriguing and warrants further investigation. This strategy ex-
tends treatment options for advanced or refractory low grade
B-cell lymphoid malignancies. Patient referral prior to the devel-
opment of refractory disease should be considered.
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION
Wagner, J.E., Brunstein, C., Barker, J. Blood and Marrow Transplant
Program, University of Minnesota, Minneapolis, MN
Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable
donors, reducing the risks of acute and chronic graft-versus-host
disease (GVHD) and improving survival. Cell dose, however, has
clearly been identiﬁed as a major limitation, often preventing the
consideration of UCB for adult recipients. Recipients of 2.5 
107 nucleated cells/kg have slow hematopoietic recovery and sig-
niﬁcantly lower incidence of engraftment. Therefore, we explored
the potential of infusing two partially HLA matched units to
augment cell dose. The underlying hypothesis is that the addition
of the second unit will enhance engraftment and speed of hema-
topoietic recovery. Thirty-one adult and adolescent patients [me-
dian age 24 years (range: 13-53); median weight 73 kg (range:
48-120)] with high-risk hematologic malignancy were transplanted
with two partially HLA-matched UCB units after myeloablative
conditioning. Patients had AML (n  15), ALL (n  12), CML (n
 3) or NHL (n  1). The median total infused dose 3.7  107
NC/kg (range 1.1-6.3) and 4.9  105 CD34/kg (range, 0.9-14.5).
All patients engrafted at a median of 23 days (range 14-41) with
one unit predominating. No factor (nucleated cell dose, CD34
cell dose, HLA-match, ABO, sex, order of infusion) predicted
which unit would predominate. Incidence of platelet recovery
(50,000/L) was 73% (95% CI, 51-95) at day 180. Incidence of
grades II-IV and III-IV acute graft-versus-host disease (GVHD)
was 65% (95% CI, 42-88) and 17% (95% CI, 2-32) at day 100.
Disease-free survival is 72% at 1 year for patients transplanted in
CR with no relapse in this cohort (median follow up: 1.2 years).
These data suggest that 1) double unit UCBT is safe with one unit
predominating over time, 2) double unit UCBT extends the ap-
plication of adults to nearly all adults and adolescents and 3)
survival exceeds historical data with a single UCB unit. Validation
studies at other centers are in progress.
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UNRELATED SINGLE CORD BLOOD TRANSPLANTS SUPPORTED BY
CO-INFUSION OF A LOW NUMBER OF MOBILIZED PERIPHERAL BLOOD
HIGHLY PURIFIED CD34 CELLS FROM A THIRD PARTY DONOR AFTER
LOW TOXICITY MYELOABLATIVE CONDITIONING
Fernandez, M.N. Hospital Universitario Puerta de Hierro, Madrid,
Spain
Late and low rate engraftment and toxicity are recognized factors
for the early TRM of unrelated CBT that has jeopardized its wide
use mostly in adults. Aside of the own nature of CB stem cells and
HLA mismatches, low cell content in the transplanted product is a
factor for graft failure and late engraftment. Our approach to solve
this problem is co-infusion of the best available CB unit (3/6
HLA mm and TNC 1.5  107/kg) and a limited number (2-2.5
 106/kg) of highly T-cell depleted (CD3 10,000/kg) mobi-
lized peripheral blood (MPB)-HSC, after a myeloablative condi-
tioning of reduced extra-hematological toxicity. The rationale is: 1)
to provide sufﬁcient immunosuppression and a high anti-tumor
chemo-radiotherapeutic effect; 2) capacity of the MPB-HSC pro-
genitors for prompt engraftment; 3) low risk of CB rejection or
GVHD by the highly T cell depleted 3rd party cells; and 4)
competitive advantage of CB progenitors for long term engraft-
ment. Data of 28 (19M, 9F) adult high risk patients consecutively
transplanted in accordance with the protocol are as follows. Me-
dian age and weight 30 years (16-60) and 67 kg (43-87). CMV
serology was positive in 24/28. Cell content of the transplanted CB
units: TNC 2.37 107/kg (1.31-3.70), CD34 cells 0.11 106/kg
(0.035-0.37). Third party donor cells infused: CD34, 2.31 
106/kg (1.05-2.58); CD3, 2.5  103/kg (0.50-9.80). The 3rd
party donor was the mother (4), other haplo-identical relative (20),
or donors with no shared haplotype (4). Initially, post-transplant
circulating granulocytes were predominantly from the 3rd party
donor in all patients except the four receiving maternal MPB
CD34 cells. For the whole group, median time for ANC/l
500, CB-ANC/l 500 and full CB chimerism were 10 (9-36),
22 and 54 days, with maximum cumulative incidences of 0.93 for
the three variables; median time to platelets 20,000/l and
50,000/l, 32 and 60 days, with maximum cumulative incidences
of 0.75 and 0.70. Excluding the 4 patients who received maternal
MPB, the corresponding data are: median time to ANC/l 500,
CB-ANC/l 500 and full CB chimerism, 9.5 (9-17), 21 and 56
days, with maximum cumulative incidences of 1.00 for the ﬁrst two
variables and 0.96 for the third; median time to platelets
20,000/l and 50,000/l: 30 and 54 days, with maximal cumu-
lative incidences of 0.83 and 0.78. Adverse effects related to the 3rd
party cells have not been recognized. Incidences of GVHD and
relapses have been low. Main cause of morbidity has been oppor-
tunistic infections not related to neutropenia. There have been 8
deaths related to the procedure. These were due to toxicity (2),
graft failure (1), GVHD II (2) and opportunistic infection (3).
After a median follow up of 10 months (1-75) for all patients and
16 months (3-75) for the 20 living (9 surviving 2 years), 4 years
OS is 67% for the whole group and 86% for the 19 after excluding
the 5 older than 40 and the 4 with mothers as the 3rd party
donors.Our strategy makes CBT feasible as a ﬁrst choice option for
most patients of a wide age range and may allow additional immu-
notherapeutic maneuvers that are being assayed.
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INCIDENCE AND RISK FACTORS FOR EARLY SEVERE INFECTIONS AF-
TER UCB
Laughlin, M. Department of Medicine and Pathology, Case Western
Reserve University, School of Medicine, Cleveland, OH
Contributing factors to bacterial, viral, and fungal infections
occurring during the ﬁrst 100 days after unrelated UCB transplan-
tation share common features to that observed after allogeneic
transplantation with conventional marrow or PBSC grafts from
adult donors. These contributing factors include host variables
(age, underlying disease), type of conditioning (ablative, reduced
intensity), duration of neutropenia, acute GVHD incidence and
severity, and receipt of corticosteroids. In addition, preliminary
clinical data point to possible unique UCB graft features contrib-
uting to infections occurring at these early time points including:
UCB stem cell and accessory cell populations, and/or graft cell
dose impacting on kinetics of myeloid and lymphocyte reconstitu-
tion. UCB graft accessory cells exhibit selective developmental
defects in several critical cell function assays potentially contribut-
ing to innate and adaptive immune reconstitution as well as
aGVHD including: Toll-like receptor expression on antigen pre-
senting cells, neutrophil adhesion molecule surface expression, T
cell Th1 cytokine production. However, whether these defects are
recapitulated in the transplant recipient has yet to be fully exam-
ined. Clear interpretation of these preliminary clinical observations
of early infections after UCB transplantation in comparison with
the published literature in allogeneic transplantation incorporating
conventional adult-derived grafts is challenged by patient selection
variables, which remain high risk in the majority of UCB patients,
particularly in the adult setting. Taken together, a full understand-
ing of the incidence and risk factors for early severe infections after
UCB transplantation awaits large multi-institutional prospective
comparison studies with conventional marrow and PBSC from
adult donors. Results of these prospective comparison trials can
then be used to prepare evidence-based guidelines for the preven-
tion of infection after UCB transplantation.
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